
-
FibroGen Inc NasdaqGS:FGEN FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Location: 350 Bay Street, San Francisco, CA, 94133, United States | Website: https://www.fibrogen.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
131.7M
Cash
33.61M
Avg Qtr Burn
-19.0M
Short % of Float
5.14%
Insider Ownership
1.72%
Institutional Own.
33.02%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Roxadustat (ROW) Details Chronic kidney disease, Anemia | Approved Quarterly sales | |
Roxadustat Details Chemotherapy Induced Anemia | PDUFA Approval decision | |
Roxadustat Details Myelodysplastic syndrome, Anemia | Phase 3 Update | |
FG-3246 (ADC) Details Cancer, Castration-resistant prostate cancer | Phase 2 Initiation | |
FG-3246+ enzalutamide Details Cancer, Castration-resistant prostate cancer | Phase 1/2 Data readout | |
FG-3165 Details Cancer, Solid tumor/s | Phase 1 Initiation | |
Pamrevlumab Details Cancer, Pancreatic cancer | Failed Discontinued | |
Pamrevlumab Details Pancreatic cancer, Cancer | Failed Discontinued | |
Roxadustat (U.S.) Details Anemia, Chronic kidney disease | Failed Discontinued | |
Pamrevlumab Details Idiopathic pulmonary fibrosis | Failed Discontinued | |
Pamrevlumab Details Duchenne muscular dystrophy | Failed Discontinued | |
Pamrevlumab Details COVID-19, Infectious disease | Failed Discontinued |